Skip to content
DraconiticResearch
Search Sources API
182,544 studies31 sourcesUpdated 10 min ago
Peer-reviewedCC BY 4.0Molecules

Heme-Binding Groups in Cytochrome P450 Inhibitors: Coordination Mechanisms, Evidence Standards and Implications for CYP19A1 Ligand Design

  • Paweł Kozyra1,2
  • Maciej Masłyk2,3
  1. 1Department of Biomedical and Analytical Chemistry, The John Paul II Catholic University of Lublin, St. Konstantynów 1j, 20-708 Lublin, Poland
  2. 2AI Drug Discovery Center, The John Paul II Catholic University of Lublin, St. Konstantynów 1j, 20-708 Lublin, Poland
  3. 3Department of Molecular Biology, The John Paul II Catholic University of Lublin, ul. Konstantynów 1i, 20-708 Lublin, Poland
Read full textPDFDOICite

Abstract

Cytochrome P450 (CYP) enzymes are heme-thiolate monooxygenases whose inhibition can result from direct reversible axial ligation of the distal heme iron, perturbation of the axial-water environment, or metabolism-dependent heme interactions. This focused review critically examines the chemical classes used as putative heme-binding groups in small-molecule CYP inhibitors, with emphasis on imidazoles, 1,2,4-triazoles, pyridines, 1,2,3-triazoles, sulfur-containing heterocycles, hydroxamates, nitriles and isonitriles. We discuss the evidential limits of ligand-induced type II spectra, distinguish direct parent–ligand coordination from mechanism-based inactivation, and outline an evidence hierarchy integrating enzymology, UV–Vis spectroscopy, EPR-based methods, structural biology and QM/MM calculations. CYP19A1 is used as a medicinal-chemistry case study illustrating how donor identity, binding geometry, scaffold recognition and selectivity against drug-metabolising and steroidogenic CYP enzymes must be optimized concurrently. We propose practical design and validation principles for the development of selectively heme-directed CYP19A1 inhibitors.

Related

  1. Rigorous Absolute Binding Free Energy Calculations Elucidate Mutation–Driven Resistance Mechanisms of Non–Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors
    Justice Josiah Mallen, Shilpa Sharma, Md Nazmul Hasan +1
    ACS OmegaPeer-reviewedCC BY 4.0Full textGeneral chemistryCrossref
  2. Understanding Polycaprolactone Degradation: Molecular Mechanisms and Implications for Biomedical Device Design
    Paulina Dziemiańczyk, Dawid Łysik, François Vernay +1
    MaterialsPeer-reviewedCC BYMaterials & polymersHAL
  3. Substrate-Engaged Formation of Reactive Oxygen Intermediates in Metalloenzymes: Mechanisms and Implications for Biocatalysis
    Wei Peng, Yuanyuan Jiang, Yulu Liu +5
    JACS AuPeer-reviewedCC BY-NC-ND 4.0Full textInorganic & organometallic chemistryCrossref
  4. Lysine Lactylation Writers: Enzymatic Versus Non-Enzymatic Mechanisms, Isomer Specificity, and Therapeutic Implications
    Dingqin Li, Shujun Zhang
    MoleculesPeer-reviewedCC BY 4.0General chemistryCrossref
  5. A Review of Antimicrobial Mechanisms of Graphene Oxide, Reduced Graphene Oxide, and Graphene Nanoplatelets: Implications for Polymer-Based Dental Materials
    Inês Côrte-Real, Driss Belayach, Ricardo Martuci +2
    NanomaterialsPeer-reviewedCC BY 4.0Materials & polymersCrossref

Cite

BibTeXRIS
BibTeX
@article{kozyra2026hemebinding,
  title = {{Heme-Binding Groups in Cytochrome P450 Inhibitors: Coordination Mechanisms, Evidence Standards and Implications for CYP19A1 Ligand Design}},
  author = {Paweł Kozyra and Maciej Masłyk},
  journal = {Molecules},
  year = {2026},
  month = oct,
  doi = {10.3390/molecules31203656},
  url = {https://www.mdpi.com/1420-3049/31/20/3656},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Heme-Binding Groups in Cytochrome P450 Inhibitors: Coordination Mechanisms, Evidence Standards and Implications for CYP19A1 Ligand Design
AU  - Paweł Kozyra
AU  - Maciej Masłyk
PY  - 2026
DA  - 2026/10/01
JO  - Molecules
DO  - 10.3390/molecules31203656
UR  - https://www.mdpi.com/1420-3049/31/20/3656
AB  - Cytochrome P450 (CYP) enzymes are heme-thiolate monooxygenases whose inhibition can result from direct reversible axial ligation of the distal heme iron, perturbation of the axial-water environment, or metabolism-dependent heme interactions. This focused review critically examines the chemical classes used as putative heme-binding groups in small-molecule CYP inhibitors, with emphasis on imidazoles, 1,2,4-triazoles, pyridines, 1,2,3-triazoles, sulfur-containing heterocycles, hydroxamates, nitriles and isonitriles. We discuss the evidential limits of ligand-induced type II spectra, distinguish direct parent–ligand coordination from mechanism-based inactivation, and outline an evidence hierarchy integrating enzymology, UV–Vis spectroscopy, EPR-based methods, structural biology and QM/MM calculations. CYP19A1 is used as a medicinal-chemistry case study illustrating how donor identity, binding geometry, scaffold recognition and selectivity against drug-metabolising and steroidogenic CYP enzymes must be optimized concurrently. We propose practical design and validation principles for the development of selectively heme-directed CYP19A1 inhibitors.
SN  - 1420-3049
ER  -